ICU Medical, Inc.: valuation
Price
$179.27
November 13, 2026Market cap $4.4B
What Ploutos Investor adds for ICU Medical
Part of Ploutos Investor, €9.99 a month
- The full history: 17 fiscal years, from 2009
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- A figure that did not match the numbers it is built from has been left out.
Valuation today
What the market pays for the company's earnings, cash flow, book value and revenue at $179.27 (November 13, 2026), beside the median of its past fiscal years.
Today's P/FCF (21.2) is 30% below the median of the chart's 3 years (30.5).
- EV / EBIT
- 47.8
- EV / Revenue
- 2.4
- Earnings yield
- –
- FCF yield
- 4.7%
- Market cap
- $4.4B
- enterprise value $5.3B
- 2025P/E–
- 2024P/E–
- 2023P/E–
| Year | Price | P/E | P/FCF | P/B | P/S |
|---|---|---|---|---|---|
| 2025 | $142.67 | – | 38.4 | 1.7 | 1.6 |
| 2024 | $155.17 | – | 30.5 | 1.9 | 1.6 |
| 2023 | $99.74 | – | 29.3 | 1.1 | 1.1 |
Each multiple at the closing price of the fiscal year's last trading day and the same year's figures. A year with a loss or negative free cash flow has no P/E or P/FCF. A P/E or P/FCF above 100 is left out: it comes from a year of near-zero earnings or cash flow and says little about the price.
Valuation against its own past
ICUI's P/E, P/FCF and P/B at each year-end price, from 2009 to 2022, 14 more fiscal years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 5 fiscal years.
What today's price assumes
The discounted cash flow model run backwards: not what the company is worth, but the growth the price takes for granted.
For a buyer at $179.27 who wants 9% a year, free cash flow would need to grow by about
+8.2%a year for ten years
Over the last 5 years it grew by -6.8% a year.
- at 7% a year
- +3.4%
- at 9% a year
- +8.2%
- at 11% a year
- +12.2%
Arithmetic on the price, not a forecast. Starts from free cash flow of $209M over the last 12 months and net debt $859M, the same growth each year for ten years, then 2.5% a year forever. Try other numbers in the DCF calculator.
DCF calculator
What is ICU Medical worth on your own assumptions?
The DCF calculator opens with the company's figures already filled in from its filings. You set how fast its cash flow grows and the return you ask for, and see the value those assumptions give.
- Free cash flow, 12 months
- $209M
- Net debt
- $859M
- Shares
- 24.69M
- FCF, 5-year average a year
- -6.8%
- Revenue, 5-year average a year
- +11.9%
- Price
- $179.27
The full analysis
What do ICU Medical's filings show?
The multiples say what the market pays for ICU Medical. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
What is ICUI's P/FCF?
ICUI's P/FCF is 21.2: a market cap of $4.4B over $209M of free cash flow in the last 12 months. Put the other way, a free cash flow yield of 4.7%.
How do I work out what ICUI is worth?
With the DCF calculator: it opens with ICU Medical's figures from its filings, you enter your assumptions for growth and the return you ask for, and see the value they give. The company pages give no price target of their own. A full analysis gives a fair-value range, which is an estimate, not a target.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. The estimated fair value, where shown, is our estimate, labelled as one: not a fact, not a score and not a recommendation to buy or sell.